Marc Tessier-Lavigne

Equibles does not estimate personal net worth.

About Marc Tessier-Lavigne

Marc Tessier-Lavigne was last confirmed as Board Member at Denali Therapeutics Inc. (DNLI) in a filing dated April 17, 2025. Regeneron Pharmaceuticals, Inc. reported in an 8-K filed September 8, 2023 that Marc Tessier-Lavigne retired as director, effective September 1, 2023.

“On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) of his decision to retire, effective as of that date, as a director of the Company.”

Regeneron Pharmaceuticals, Inc. Form 8-K, filed September 8, 2023 · Read the filing

Affiliation history

Denali Therapeutics Inc. (DNLI)
Board Member

Proxy statement

2015-01-01–2025-04-17

Last confirmed by a filing; no departure on record

Company network

Denali Therapeutics Inc.

DNLI

Biotechnology · Healthcare

Board Member

Since 2015-01-01, last confirmed 2025-04-17

Recent activity

Executive change Retired: director Regeneron Pharmaceuticals, Inc. (REGN)
2023-09-01